Two Sigma Advisers’s Genocea Biosciences, Inc. GNCA Stock Holding History

Two Sigma Advisers’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$13K	–	3008
2022 Q1	$13K	Sell	10,000 -12,677	-56%	-$13.8K	﹤0.01%	2688
2021 Q4	$26K	Sell	22,677 -119,800	-84%	-$179K	﹤0.01%	2533
2021 Q3	$274K	Sell	142,477 -106,000	-43%	-$208K	﹤0.01%	2147
2021 Q2	$581K	Sell	248,477 -156,000	-39%	-$376K	﹤0.01%	1876
2021 Q1	$1.1M	Buy	404,477 +193,800	+92%	+$574K	﹤0.01%	1607
2020 Q4	$510K	Buy	210,677 +136,000	+182%	+$310K	﹤0.01%	1856
2020 Q3	$171K	Buy	+74,677	New	+$196K	﹤0.01%	2189
2018 Q3	–	Sell	-2,785	Closed	-$19K	–	2493
2018 Q2	$19K	Buy	2,785 +1,072	+63%	+$8.02K	﹤0.01%	2326
2018 Q1	$14K	Buy	+1,713	New	+$14.2K	﹤0.01%	2282

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Two Sigma Advisers's GNCA Position: Q2 2022 in Review

Two Sigma Advisers sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 10,000 shares — an estimated $13K sold.

Two Sigma Advisers first reported a position in GNCA in Q1 2018 and held it in 9 quarters. The position peaked at $1.1M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Two Sigma Advisers reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 10,000 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $13K.
Two Sigma Advisers first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 9 quarters.
Two Sigma Advisers's Genocea Biosciences, Inc. position peaked at $1.1M in Q1 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.